Challenges in the care of patients with RET-altered thyroid cancer: a multicountry mixed-methods study

Murray, Suzanne; Subbiah, Vivek; Sherman, Steven I.; Péloquin, Sophie; Sireci, Anthony; Grohé, Christian; Bubach, Patrick; Lazure, Patrice

doi:10.1186/s13044-023-00166-4

Thyroid Research

Table 3 Percent of providers reporting suboptimal knowledge in the care of patients with RET-altered thyroid cancer.

From: Challenges in the care of patients with RET-altered thyroid cancer: a multicountry mixed-methods study

		GER		UK		JPN		US		Total
Sub-optimal knowledge of:	Profession	%	n	%	n	%	n	%	n	%	n	Sig.
Screening tools for TC	MED. ONC	57	44	37	41	-	-	36	44	43	129	0.087
	ENDO	35	26	27	41	67	43	19	43	37	153	> 0.001*
	PATH	-	-	-	-	-	-	-	-	-	-	-
Genetic risk factors of TC	MED. ONC	68	44	56	43	-	-	39	44	54	131	0.020*
	ENDO	54	26	51	41	78	43	46	44	57	154	0.019*
	PATH	-	-	-	-	-	-	-	-	-	-	-
Genetic biomarker tests for TC	MED. ONC	52	44	52	44	-	-	44	45	50	133	0.694
	ENDO	50	26	48	41	77	43	39	44	62	154	> 0.001*
	PATH	30	20	73	11	79	29	53	30	59	90	0.004*
Tests required in order to initiate treatment for TC	MED. ONC	55	44	40	43	-	-	42	45	46	132	0.322
	ENDO	54	26	42	41	62	42	25	44	44	153	0.005*
	PATH	30	20	73	11	76	29	70	30	63	90	0.006*
Specific mechanisms of action of multi-kinase inhibitors for TC	MED. ONC	50	44	41	44	-	-	42	45	44	133	0.650
	ENDO	58	26	73	40	69	42	76	41	70	149	0.455
	PATH	40	20	82	11	83	29	72	29	70	89	0.009*
Specific mechanisms of action of selective RET inhibitors for TC	MED. ONC	61	44	47	44	-	-	44	45	54	133	0.252
	ENDO	68	25	83	40	46	41	77	39	77	145	0.608
	PATH	50	20	75	8	78	27	83	29	73	84	0.071
National guidelines for the management of TC	MED. ONC	41	44	32	44	-	-	38	45	37	133	0.668
	ENDO	42	26	37	41	56	43	33	43	42	153	0.142
	PATH	35	20	82	11	84	30	72	29	69	90	0.002*
International guidelines for the management of TC	MED. ONC	39	44	50	44	-	-	49	45	46	133	0.498
	ENDO	46	26	44	41	69	43	58	43	56	153	0.078
	PATH	55	20	91	11	97	30	83	29	82	18	0.002*
Side effects of multi-kinase inhibitors	MED. ONC	46	44	34	44	-	-	39	44	39	132	0.547
	ENDO	77	26	80	40	79	42	76	41	78	149	0.969
	PATH	-	-	-	-	-	-	-	-	-	-	-
Side-effects of selective RET inhibitors	MED. ONC	64	44	52	44	-	-	41	44	52	132	0.103
	ENDO	80	25	88	40	85	41	77	39	83	145	0.596
	PATH	-	-	-	-	-	-	-	-	-	-	-
Ongoing clinical trials on selective RET inhibitors	MED. ONC	67	43	73	44	-	-	61	44	67	131	0.525
	ENDO	87	23	90	40	90	40	85	39	88	142	0.861
	PATH	45	20	86	7	86	27	90	29	77	82	0.002*

GER = Germany, UK = United Kingdom, JPN = Japan, US = United States.
* significant difference between countries (p<0.05) bold for % and italics for n were used to increase legibility of the table.

Back to article page

ISSN: 1756-6614

Contact us

General enquiries: journalsubmissions@springernature.com